Illumina CEO: Array Market Returned to 'Normalcy' in 2010 as BeadChip Sales Rose 10 Percent
January 18, 2011
Illumina CEO: Array Market Returned to 'Normalcy' in 2010 as BeadChip Sales Rose 10 Percent
CEO Jay Flatley told investors at the JP Morgan Healthcare Conference in San Francisco last week that "2009 was a challenging year for us in the array business," but that 2010 was a "year when the market returned to some degree of normalcy."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Illumina to Remain Secure if NIH Budget Shrinks as Projected, CEO Predicts
September 20, 2011 / BioArray News - Illumina's Q2 Sales Rise 36 Percent on Sequencing Demand, 'Overall Improvement' in Array Sales
August 2, 2011 / BioArray News - Illumina CEO 'Optimistic' about Array Business as Q1 Sales Spike 47 Percent
May 3, 2011 / BioArray News - 'Soft' Q1 Pushes Affymetrix to Bet on Applied Markets, Acquisitions to Restore Growth
May 3, 2011 / BioArray News - Illumina Q3 Chip Sales Fall 9 Percent, Though Exome Array Orders Spike
October 25, 2011 / BioArray News